The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris.

Giulio FortunaElena CalabriaElvira RuoppoDaniela AdamoMassimo AriaMassimo AmatoMichele D Mignogna

Published in: Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (2019)

RTX represents a valid and safe alternative as an adjuvant in OPV patients with low rate of relapses and side effects.

Keyphrases

early stage
diffuse large b cell lymphoma
combination therapy
hodgkin lymphoma